Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.

Biotech stocks are tricky investment bets that require careful analysis and scrutiny. Here's a list of biotech stocks that were among the worst performers in the first half but have the potential to come back stronger: